Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06293620
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
PF-06293620 is a humanized IgG2Δa monoclonal antibody developed by Pfizer as a glucagon receptor antagonist for the treatment of type 2 diabetes mellitus. It binds to and blocks the human glucagon receptor, thereby inhibiting glucagon signaling. This mechanism reduces hyperglycemia by normalizing dysregulated hepatic glucose production, independent of pancreatic beta cell function. The drug was administered subcutaneously in clinical trials and demonstrated robust lowering of fasting plasma glucose (FPG) and HbA1c in subjects with type 2 diabetes mellitus on stable metformin therapy. Development reached Phase 1 clinical trials but has not progressed further[1][3][4].
- Other names
- RN909RN-909RN 909
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on PF-06293620.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06293620.